VISTA, as a novel B7 family checkpoint, has emerged as a promising target for cancer immunotherapy, with several VISTA inhibitors (monoclonal antibodies, small molecules, and fusion proteins) currently in preclinical or early clinical development (45). The gene discussed is VSIR; the disease is cancer.